Besides, it has been confirmed that isolated small peptides derived from the extracellular domain of TMED10 could treat cancers with abnormal TGF-β signaling activity by antagonizing TGF-β signaling (Nakano et al., 2017). The gene discussed is TMED10; the disease is cancer.